dHER2 vaccine

The dHER2 vaccine is a DNA-based cancer vaccine designed to target the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in certain types of breast cancer. The mechanism of action involves delivering DNA encoding the intracellular domain of the HER2 protein into host cells, prompting them to produce and present this antigen to the immune system. This stimulates both cytotoxic T-cell and B-cell responses against HER2-expressing tumor cells, aiming to prevent recurrence or progression of HER2-positive breast cancer after standard treatments such as surgery and trastuzumab therapy. The dHER2 vaccine has demonstrated safety and immunogenicity in early-phase clinical trials, with ongoing research evaluating its efficacy in preventing disease recurrence[1][4][5].

Other names

HER2 DNA vaccineHER-2 DNA vaccineHER 2 DNA vaccineHER2-targeted DNA vaccineHER-2-targeted DNA vaccineHER 2-targeted DNA vaccine